| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to tre... |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat... |
| 17 Jul 2026 |
8-K: Other Events
We have acted as counsel to Tvardi Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate... |
| 17 Jul 2026 | 424B5 |
| 07 Jul 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat... |
| 11 Jun 2026 |
Form 4: Shiff Susan Ph.D., Director
Granted 6,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Smith Cynthia, Director
Granted 6,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Shah Sujal, Director
Granted 6,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Hall Wallace L Jr, Director
Granted 6,000 Stock Option (right to buy) |
| 11 Jun 2026 |
Form 4: Wyzga Michael S, Director
Granted 6,000 Stock Option (right to buy) |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Tvardi Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the four proposals set forth below. A more detailed des... |
| 13 May 2026 | EFFECT |
| 12 May 2026 | EFFECT |
| 08 May 2026 | POS AM |
| 08 May 2026 | CORRESP |
| 08 May 2026 | 10-Q |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June |
Loading...